View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 10, 2021updated 12 Jul 2022 11:18am

Telix begins Phase III prostate cancer treatment trial

Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant prostate cancer (mCRPC) patients.

Telix Pharmaceuticals has begun a Phase III ProstACT clinical trial of its therapy candidate, TLX591 (177Lu-DOTA-rosopatamab), in advanced metastatic castrate-resistant prostate cancer (mCRPC) patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial initiation comes after approval from the Human Research Ethics Committee (HREC) and clearance of Clinical Trial Notification (CTN) from the Australian Therapeutic Goods Administration (TGA).

An antibody-based radioimmunoconjugate or molecularly targeted radiotherapy (MTR), TLX591 targets prostate-specific membrane antigen (PSMA).

PSMA is a cancer target that is frequently found in metastatic prostate cancer patients.

The international, multi-centre randomised controlled Phase III trial will have around 390 subjects selected with the help of 68Ga-PSMA imaging with TLX591- companion diagnostics (CDx), Illuccix.

A lead investigational product of Telix, Illuccix is intended for prostate cancer imaging. It is currently under the TGA’s priority evaluation.

The trial subjects will be PSMA-expressing mCRPC patients whose disease had progressed after receiving a novel androgen axis drug (NAAD) as the previous treatment.

The trial will assess standard of care (SOC) therapy plus TLX591 versus SOC therapy alone.

Radiographic progression-free survival will form the trial’s primary endpoint while secondary endpoints will be overall survival and quality-of-life assessment.

Telix Pharmaceuticals CEO Dr Christian Behrenbruch said: “ProstACT builds on a significant body of clinical data for TLX591, which to date has been studied in over 200 patients with advanced prostate cancer, across five previous studies.

“TLX591 has demonstrated promising and competitive clinical potential that we believe warrants further confirmation in this second-line disease setting.”

The company initiated the trial sites in Australia and plans to gradually include more sites across the globe during the second half of this year on obtaining necessary approvals.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena